MLP - MultiPlex Respiratory Lite Panel 7 Pathogens icluding COVID-19 Assay, 384 well, 48 panels per plate

Product Description

The COVID-19 Respiratory Lite Panel is an in-vitro multiplex real-time reverse transcription polymerase chain reaction (rRT-PCR) assay for the qualitative identification of nucleic acids from organisms frequently found in the respiratory tract. This method is highly accurate, analytically sensitive, and is used to identify organisms by amplifying and detecting genetic material of pathogens in samples. The panel will aid in the research of causative agents of respiratory tract infections and their prevalence.

The target organisms included in this panel are as follows: Haemophilus influenzae, Influenza A&B, Moraxella catarrhalis, Mycoplasma pneumoniae, SARS-CoV-2 (COVID-19), Streptococcus pyogenes (Group A Strep) and RSV.

Usage Information

	Reagent Storage and Use Guidelines
	Store all reagents at -25°C to -15°C Do not freeze-thaw plates more than 3 times.
	The Following is Included in the Kit
	384-well PCR plate pre-loaded with the COVID-19 Respiratory Lite Microbiota assays and positive and negative controls.
	The Following is Supplied by the User: Materials
	Extracted Sample(s) qPCR optical film Sealer for optical film
	Equipment
	Manual defrost -20°C freezer Laminar Flow or PCR Dead Air Box for general plate setup. Do not use Laminar Flow for infectious samples Pipettes and appropriate filtered pipette tips Plate Vortex Plate centrifuge Lab utility knife
	Instrumentation
	CFX384 Touch Real-Time PCR Detection System

Download Product Information Respiratory Panel

Limitations of Use
This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; This product has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §
360bbb3(b)(1), unless the declaration is terminated or authorization is revoked sooner.